- Home
- AMLX vs ALMS Comparison
AMLX vs ALMS Comparison
Compare AMLX & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- ALMS
- Stock Information
- Founded
- AMLX 2014
- ALMS 2021
- Country
- AMLX United States
- ALMS United States
- Employees
- AMLX N/A
- ALMS N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- ALMS
- Sector
- AMLX Health Care
- ALMS
- Exchange
- AMLX Nasdaq
- ALMS NYSE
- Market Cap
- AMLX 459.1M
- ALMS 402.6M
- IPO Year
- AMLX 2022
- ALMS 2024
- Fundamental
- Price
- AMLX $4.49
- ALMS $4.46
- Analyst Decision
- AMLX Buy
- ALMS Strong Buy
- Analyst Count
- AMLX 5
- ALMS 7
- Target Price
- AMLX $9.60
- ALMS $28.00
- AVG Volume (30 Days)
- AMLX 1.0M
- ALMS 410.3K
- Earning Date
- AMLX 05-08-2025
- ALMS 05-19-2025
- Dividend Yield
- AMLX N/A
- ALMS N/A
- EPS Growth
- AMLX N/A
- ALMS N/A
- EPS
- AMLX N/A
- ALMS N/A
- Revenue
- AMLX N/A
- ALMS N/A
- Revenue This Year
- AMLX N/A
- ALMS N/A
- Revenue Next Year
- AMLX N/A
- ALMS N/A
- P/E Ratio
- AMLX N/A
- ALMS N/A
- Revenue Growth
- AMLX N/A
- ALMS N/A
- 52 Week Low
- AMLX $1.58
- ALMS $3.18
- 52 Week High
- AMLX $7.27
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- AMLX 49.58
- ALMS N/A
- Support Level
- AMLX $4.41
- ALMS N/A
- Resistance Level
- AMLX $4.95
- ALMS N/A
- Average True Range (ATR)
- AMLX 0.42
- ALMS 0.00
- MACD
- AMLX -0.10
- ALMS 0.00
- Stochastic Oscillator
- AMLX 16.54
- ALMS 0.00
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.